Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers
A Prospective, Randomized, Comparative Parallel Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lawrence Didomenico, DPM
- Phone Number: 3307274148
Study Contact Backup
- Name: Maura Maloney, JD
- Phone Number: 3307160203
Study Locations
-
-
Ohio
-
Canfield, Ohio, United States, 44406
- Recruiting
- Lower Extremity Institute of Research and Therapy
-
Contact:
- Maura Maloney, JD
- Phone Number: 3307160203
-
Contact:
- Lawrence Didomenico, DPM
- Phone Number: 330-727-4148
-
Principal Investigator:
- Lawrence DiDomenico, DPM
-
-
Virginia
-
Danville, Virginia, United States, 24112
- Recruiting
- Martinsville Research Institute
-
Contact:
- Nathan Young, DPM
- Phone Number: 540-676-5886
-
Contact:
- Kimberly Young
- Phone Number: (540) 676-5886
-
Principal Investigator:
- Nathan Young, DPM
-
Troutville, Virginia, United States, 24019
- Recruiting
- Shenandoah Lower Extremity Research Institute
-
Contact:
- Jennifer Keller, DPM
- Phone Number: 540-529-6155
-
Contact:
- Hillary Dillow
- Phone Number: 540-904-1458
-
Principal Investigator:
- Jennifer Keller, DPM
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients age 18 or older.
- Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study.
- Patient's ulcer must be diabetic in origin and larger than 1 cm2.
- Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
- Ulcer must be present for a minimum of four weeks before enrollment randomization, with documented failure of conventional ulcer therapy to heal the wound.
- A two week run-in period will precede enrollment/ randomization in the trial to document the indolent nature of the wounds selected.
- Additional wounds may be present but not within 3 cm of the study wound.
- Wound must be present anatomically on the foot as defined by beginning below the malleoli of the ankle and be neuropathic in origin.
- Patient's ulcer must exhibit no clinical signs of infection.
- Serum Creatinine less than 3.0mg/dl within last six months.
- HbA1c less than or equal to 12% within last 90 days.
Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days:
- Dorsum transcutaneous oxygen test (TcPO2) with results ≥30mmHg,
- ABIs with results of ≥0.7 and ≤1.2, OR
- Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg
Exclusion Criteria:
- Patients presenting with an ulcer probing to tendon, muscle, capsule or bone (UT Grade IIIA-D). A positive probe-to-bone will be confirmed when bone or joint can be felt with a sterile, ophthalmological probe.
- Patients whose index diabetic foot ulcers are greater than 25 cm2.
- Patients considered not in reasonable metabolic control, confirmed by an HbA1c greater than 12% within previous 90 days.
- Patients whose serum creatinine levels are 3.0mg/dl or greater within the last six months.
- Patients with a known history of poor compliance with medical treatments.
- Patients who have been previously randomized into this study, or are presently participating in another clinical trial.
- Patients who are currently receiving radiation therapy or chemotherapy.
- Patients with known or suspected local skin malignancy to the index diabetic ulcer.
- Patients diagnosed with autoimmune connective tissues diseases.
- Non-revascularizable surgical sites.
- Active infection at site.
- Any pathology that would limit the blood supply and compromise healing.
- Patients that have received a biomedical or topical growth factor for their wound within the previous 30 days.
- Patients who are pregnant or breast feeding.
- Patients who are taking medications that are considered immune system modulators which could affect graft incorporation.
- Patients with known hypersensitivity to components of any treatment used in the trial.
- Wounds greater than one year in duration without intermittent healing.
- Wounds improving greater than 20% over the first two weeks (run-in period) of the trial using standard of care dressing and camboot.
- Patients taking Cox-2 inhibitors.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Standard of Care
Surgical debridement of diabetic foot ulcer, followed by collagen alginate and gauze dressing application to be changed daily by patient.
Patient will practice offloading, reassessment weekly at office visit
|
Provision of an offloading cam walker or cast boot, may also convert to "total contact cast" and add felt or foam to supplement
|
|
Experimental: Amniotic Membrane / Amnioband
Application of Amnioband with dressing application, to be changed weekly following surgical debridement.
Patient will practice offloading.
If the ulcer is not closed completely Amnioband will be applied weekly at weeks 2-11
|
Provision of an offloading cam walker or cast boot, may also convert to "total contact cast" and add felt or foam to supplement
Application of a non adherent dressing, and a multi-layer compression dressing
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of ulcers completely healed by amniotic memrane versus standard care
Time Frame: 6 weeks
|
The primary objective of this study is to compare the proportion of ulcers completely healed by the amniotic membrane graft protocol of care to the standard protocol of care in the management of indolent diabetic ulcers at 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of ulcers healed by amniotic membrane versus standard care
Time Frame: 12 weeks
|
The secondary objectives of this study are to compare the proportion of healing at 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Lawrence Didomenico, DPM, Medical Director
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 001 (Marta Eliza Miller Foundation)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.